Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÇelik, Serhat
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorGüven, Zeynep Tuğba
dc.contributor.authorKeni Beğendi, Nermin
dc.contributor.authorDemir, Fatma
dc.contributor.authorKeklik, Muzaffer
dc.contributor.authorÜnal, Ali
dc.date.accessioned2023-12-11T12:14:19Z
dc.date.available2023-12-11T12:14:19Z
dc.date.issued2023en_US
dc.identifier.citationÇelik, S., Kaynar, L., Güven, Z. T., Begendi, N. K., Demir, F., Keklik, M., & Ünal, A. (2023). The impact of diabetes mellitus on hematopoietic stem cell mobilization, a-single center cohort study. Transfusion and Apheresis Science, 103838.en_US
dc.identifier.issn1473-0502
dc.identifier.urihttps://dx.doi.org/ 10.1016/j.transci.2023.103838.
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1825
dc.description.abstractBackground: Factors such as age, underlying hematological disease, chemotherapy and radiotherapy used, and bone marrow infiltration may cause mobilization failure. Several preclinical observed that diabetes mellitus (DM) leads to profound remodeling of the hematopoietic stem cell (HSC) niche, resulting in the impaired release of HSCs. We aim to examine the effect of DM on HSC mobilization and to investigate whether there is a relationship between complications developing in the DM process and drugs used to treat DM and mobilization failure. Methods: In Erciyes University Bone Marrow Transplantation Unit, 218 patients who underwent apheresis for stem cell mobilization between 2011 and 2021 were evaluated retrospectively. One hundred and nine patients had a diagnosis of DM, and 109 did not. Results: Mobilization failure developed in 17 (15.6 %) of the patients in the DM group, while it developed in 7 (6.4 %) patients in the non-DM group (p = 0.03). CD34+ stem cell count was 8.05 (1.3-30.2) × 106/kg in the DM group, while it was 8.2 (1.7-37.3) × 106/kg in the other group (p = 0.55). There was no statistically significant relationship between glucose and hemoglobin A1c levels and the amount of CD34+ cells (p = 0.83 and p = 0.14, respectively). Using sulfonylurea was the only independent predictor of mobilization failure (OR 5.75, 95 % CI: 1.38-24.05, p = 0.02). Conclusion: DM should be considered a risk factor for mobilization failure. Further research is needed fully to understand the mechanisms underlying the mobilization failure effects of sulfonylureas and to develop strategies to improve stem cell mobilization in diabetic patients.en_US
dc.language.isoengen_US
dc.publisherElsevier Scienceen_US
dc.relation.isversionof10.1016/j.transci.2023.103838.en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectHematopoietic Stem Cellen_US
dc.subjectMobilizationen_US
dc.subjectSulfonylureaen_US
dc.titleThe impact of diabetes mellitus on hematopoietic stem cell mobilization, a-single center cohort studyen_US
dc.typearticleen_US
dc.authorid0000-0002-7570-1552en_US
dc.departmentAFSÜen_US
dc.contributor.institutionauthorKeni Beğendi, Nermin
dc.identifier.volume62en_US
dc.identifier.issue6en_US
dc.relation.journalTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresisen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster